NeuroPace (NPCE) Common Equity (2020 - 2026)

NeuroPace's Common Equity history runs 7 years deep, the most recent figure standing at $14.5 million for Q1 2026.

• On a quarterly basis, Common Equity fell 40.44% year-over-year to $14.5 million in Q1 2026; TTM through Mar 2026 was $14.5 million, a 40.44% decrease from a year earlier, with the FY2025 full-year figure at $19.0 million, up 137.5% from the prior year.
• Common Equity eased to $14.5 million in Q1 2026 per NPCE's latest filing, from $19.0 million in the prior quarter.
• Across five years, Common Equity topped out at $62.8 million in Q1 2022 and bottomed at $8.0 million in Q4 2024.
• The 5-year median for Common Equity is $19.4 million (2025), against an average of $24.6 million.
• Across the five-year window, Common Equity surged 140.16% in 2022 and slumped 62.31% in 2023, its largest moves.
• Year by year, Common Equity stood at $34.8 million in 2022, then slumped by 40.61% to $20.7 million in 2023, then tumbled by 61.2% to $8.0 million in 2024, then soared by 137.5% to $19.0 million in 2025, then fell by 24.05% to $14.5 million in 2026.
• Per Business Quant, the three latest NPCE Common Equity figures stand at $14.5 million (Q1 2026), $19.0 million (Q4 2025), and $18.5 million (Q3 2025).